Stabilis
Hydrocortisone sodium succinate
Noms commerciaux Actocortina Espagne Androcortil Brésil
Corticina Vénézuela
Cortop Italie
Drosodin Mexique
Efcortesol Grande Bretagne
Extaden Mexique
Flebocortid Italie, Maroc, Mexique Fridalit Argentine, Pérou
Hialub Chili
Hycort Vénézuela
Hydrocort France
Inotid Mexique
Itrocsona Colombie
Novocortil Pérou
Solu Cortef Afrique du sud, Arabie Saoudite, Australie, Belgique, Canada, Chili, Colombie, Croatie, Danemark, Emirats Arabes Unis , Etats Unis d’Amérique, Finlande, Grande Bretagne, Grèce, Islande, Italie, Luxembourg, Norvège, Pays bas, Portugal, Suède, Suisse
Sonatalis Mexique
Stricort Malaisie, Vénézuela Stabilité des solutions
1 mg/ml 25°C 3 739
1 mg/ml 25°C 3 739
1 mg/ml 25°C 24 739
2 mg/ml 23°C 24 31
2 mg/ml 4°C 48 31
1 mg/ml 25°C 7 2001
1 mg/ml 7°C 41 2001
50 mg/ml 25°C 6 2001
50 mg/ml 5°C 81 2001
1 mg/ml 25°C 6 2001
1 mg/ml 7°C 48 2001
10 mg/ml 25°C 3 2354
10 mg/ml 5°C 21 2354
2 mg/ml 23°C 24 31
2 mg/ml 4°C 48 31
Stabilité en mélange
0,478 mg/ml 23°C Methotrexate sodium : 0,0314 mg/ml
Cytarabine : 0,484 mg/ml 48 1661
0,467 mg/ml 23°C Methotrexate sodium : 0,0581 mg/ml
Cytarabine : 0,477 mg/ml 48 1661
0,489 mg/ml 23°C Methotrexate sodium : 0,0721 mg/ml
Cytarabine : 0,479 mg/ml 48 1661
0,478 mg/ml 4°C Methotrexate sodium : 0,0314 mg/ml
Cytarabine : 0,484 mg/ml 48 1661
0,467 mg/ml 4°C Methotrexate sodium : 0,0581 mg/ml
Cytarabine : 0,477 mg/ml 48 1661
0,489 mg/ml 4°C Methotrexate sodium : 0,0721 mg/ml
Cytarabine : 0,479 mg/ml 48 1661
10 mg/ml 25°C Metronidazole : 5 mg/ml 7 631
10 mg/ml 5°C Metronidazole : 5 mg/ml 12 631
2 mg/ml 25°C Methotrexate sodium : 1 mg/ml
Cytarabine : 4,1 mg/ml 24 1028
2 mg/ml 25°C Methotrexate sodium : 1 mg/ml
Cytarabine : 4,1 mg/ml 24 1028
2 mg/ml 25°C Methotrexate sodium : 1 mg/ml
Cytarabine : 4,1 mg/ml 24 1028
Incompatibilités
Hydrocortisone sodium succinate
Amoxicillin sodium / clavulanic acid 3545
Hydrocortisone sodium succinate
Bleomycin sulfate 4154
Hydrocortisone sodium succinate : 50 mg/ml
Ciprofloxacin lactate : 2 mg/ml 288
Hydrocortisone sodium succinate
Cytarabine 3580
Hydrocortisone sodium succinate
Dacarbazine 3267
Hydrocortisone sodium succinate
Dacarbazine 3605
Hydrocortisone sodium succinate
Daunorubicin hydrochloride 3604
Hydrocortisone sodium succinate : 50 & 125 mg/ml
Diltiazem hydrochloride : 5 mg/ml 198
Hydrocortisone sodium succinate : 0.01 mg/ml
Ergotamine tartrate : 0.5 mg/ml 1228
Hydrocortisone sodium succinate : 0.01 mg/ml
Ergotamine tartrate : 0.5 mg/ml 1228
Hydrocortisone sodium succinate : 0.01 mg/ml
Ergotamine tartrate : 0.5 mg/ml 1228
Hydrocortisone sodium succinate
Heparin sodium 3540
Hydrocortisone sodium succinate : 2 & 50 mg/ml
Idarubicin hydrochloride : 1 mg/ml 491
Hydrocortisone sodium succinate : 1 mg/ml
Imipenem-Cilastatin / Relebactam : 5 mg/ml 4433 Hydrocortisone sodium succinate : 1 mg/ml
Labetalol hydrochloride : 5 mg/ml 3879
Hydrocortisone sodium succinate : 1 mg/ml
Lansoprazole : 0.55 mg/ml 1625
Hydrocortisone sodium succinate
Magnesium sulfate 3838
Hydrocortisone sodium succinate : 50 mg/ml
Midazolam hydrochloride : 5 mg/ml 186
Hydrocortisone sodium succinate : 1 mg/ml
Oritavancin : 0.8 >>2 mg/ml 3152
Hydrocortisone sodium succinate
Pantoprazole sodium 2090
Hydrocortisone sodium succinate
Rocuronium bromide 3564
Hydrocortisone sodium succinate : 1 mg/ml
Sargramostim : 10 µg/ml 335
Hydrocortisone sodium succinate : 125 mg/ml
Thiopental sodium : 25 mg/ml 3767
Hydrocortisone sodium succinate
Vancomycin hydrochloride 3588
Voie d’administration
Bibliographie
Type Source
31 Revue Zhang Y, Xu QA, Trissel LA, Gilbert DL.
Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution.
Hosp Pharm 1996 ; 31: 965-970.
186 Revue Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198 Revue Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
288 Revue Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
491 Revue Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
631 Revue Das Gupta V, Stewart KR.
Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion.
J Parenter Sci Technol 1985 ; 39: 145-148.
739 Revue Cradock JC, Kleinmann LM, Rahman A.
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate.
Am J Hosp Pharm 1978 ; 35: 402-406.
1028 Revue Cheung YW, Vishnuvajjala BR, Flora KP.
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures.
Am J Hosp Pharm 1984 ; 41: 1802-1806.
1228 Revue Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1661 Revue Trissel LA, King KM, Zhang Y, Wood AM.
Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use.
J Oncol Pharm Practice 2002 ; 8: 27-32.
2001 Revue Rigge DC, Jones MF.
Shelf lives of aseptically prepared medicines - stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes.
J Pharm Biomed Anal 2005 ; 38: 332-336.
2090 Revue Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2354 Revue Das Gupta V, Ling J.
Stability of hydrocortisone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Int J Pharm Compound 2000 ; 4, 5: 396-397.
3152 Revue Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3267 Laboratoire Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3540 Laboratoire Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3545 Laboratoire Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3564 Laboratoire Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3580 Laboratoire Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3588 Laboratoire Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3604 Laboratoire Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3605 Laboratoire Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3767 Revue Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3838 Laboratoire Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3879 Revue Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
4154 Laboratoire Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4254 Revue D'Huart E, Vigneron J, Demor? B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4433 Revue Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
Stabilis
Hydrocortisone sodium succinate
Stabilité des préparations
100 mg Hydrocortisone Upjohn® Acide citrique 200 mg Eau purifiée >> 100 mL
NaOH 1N >> pH 5,5 3-7°C 21 4416
100 mg Hydrocortisone Upjohn® Acide citrique 200 mg Eau purifiée >> 100 mL
NaOH 1N >> pH 6,5 3-7°C 21 4416
100 mg Hydrocortisone Upjohn® Eau ppi >> 100 mL Acide chlorhydrique 1N >> pH 4 3-7°C 14 4416
Bibliographie
Type Source
4416 Revue Chappe J, Osman N, Cisternino S, Fontan J-E, Schlatter J.
Stability of Hydrocortisone Preservative-Free Oral Solutions.
J Pediatr Pharmacol Ther 2015 ; 20, 3: 197-202.
